Browse studies

Find your next paid study

37 recruiting studies matching your filters

A Phase 1b Dose Escalation and Expansion Study of IMGN151 as Monotherapy and in Combination With Other Anti-Cancer Therapies in Subjects With Gynecologic Cancers

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety and tolerability …

Gynecologic CancersPlatinum-Sensitive Ovarian CancerFallopian Tube Cancer+1 more

A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (DENALI / ZN-c3-005 / GOG-3066)

This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, F…

High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Estimated

~$10 – $8,750

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncNCT05128825

Phase 2

A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects With FRα-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy …

Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer+1 more

A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-021 as a Single Agent and in Combination Therapy in Patients With Advanced Solid Tumors

This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and a…

Advanced Solid TumorHR+/HER2- Breast CancerHR+, HER2-, Advanced Breast Cancer+6 more

Estimated

~$10 – $8,750

Avenzo Therapeutics, Inc.NCT05867251

Phase 1

A Phase 1/2 Study of REGN4018 (Ubamatamab), a MUC16×CD3 Bispecific Antibody, Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers

The main purpose of this study is to: * Learn about the safety of ubamatamab and to find out what dose of ubamatamab can be given alone or with cemiplimab to …

Recurrent Ovarian CancerRecurrent Fallopian Tube CancerRecurrent Primary Peritoneal Cancer+3 more

Estimated

~$10 – $8,750

Regeneron PharmaceuticalsNCT03564340

Phase 1

A Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific Antibody) Administered in Combination With Other Agents in MUC16 + Malignancies

This study is researching an investigational drug called REGN5668 : * alone or, * combined with cemiplimab (also known as REGN2810) or, * combined with both c…

Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer+1 more

Estimated

~$10 – $8,750

Regeneron PharmaceuticalsNCT04590326

Phase 3

A Phase 3, Randomized, Open-label Study of Raludotatug Deruxtecan (MK-5909, R-DXd) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly-Diagnosed Advanced Non-HRD-Positive Ovarian Cancer Following First-line Platinum-based Chemotherapy (ENGOT-ov102/MITO/GOG-3141/ REJOICE-Ovarian 04)

Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible.…

Ovarian CancerOvarian NeoplasmsPeritoneal Cancer+1 more

Estimated

~$10 – $8,750

Merck Sharp & Dohme LLCNCT07776691

Phase 1

Phase II Study Evaluating the Effect of IMNN-001 on Second Look Laparoscopy (SLL) in Combination With Bevacizumab (BEV) and Neoadjuvant Chemotherapy (NACT) in Newly Diagnosed With Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

This is a 1:1 randomized, open label, multi-center phase I/II trial to evaluate the safety, dosing, efficacy, and biological activity of adding IMNN-001 to che…

Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer

Multi-Arm Phase 2 Platform Study of Ubamatamab (REGN4018; MUC16×CD3 Bispecific Antibody) With or Without Additional Agents in Platinum-Resistant Ovarian Cancer

This study is researching an experimental drug called ubamatamab, also referred to as "study drug". The study is focused on participants who have advanced ovar…

Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer

Estimated

~$10 – $8,750

Regeneron PharmaceuticalsNCT06787612

Phase 3

Laparoscopic Cytoreduction After Neoadjuvant Chemotherapy

This phase III trial compares minimally invasive surgery (MIS) to laparotomy in treating patients with stage IIIC-IV ovarian, primary peritoneal, or fallopian …

Advanced Ovarian CarcinomaFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid Tumor+22 more

Estimated

Phase 3

A Randomised, Open-label, Phase III Study of Torvutatug Samrotecan With or Without Bevacizumab Versus Standard of Care as Second- or Third-Line Maintenance Treatment in Participants With Platinum-sensitive Relapsed Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (TREVI-OC-03)

The purpose of this study is to measure the efficacy and safety of torvutatug samrotecan (torvu-sam) with or without bevacizumab compared to standard of care (…

Platinum-sensitive Relapsed Epithelial Ovarian CancerPlatinum-sensitive Relapsed Fallopian Tube CancerPlatinum-sensitive Relapsed Primary Peritoneal Cancer

Estimated

~$10 – $7,500

AstraZenecaNCT07816666

Phase 2

Targeting Immune Modulation in High Grade Serous Carcinoma: Combined Effects of Chemotherapy and Atorvastatin

The goal of this clinical trial is to learn how atorvastatin in patients with advanced high grade serous cancer of the ovary, fallopian tube, or peritoneum cha…

Ovarian CancerFallopian Tube CancersPrimary Peritoneal Cancer+1 more

Estimated

~$10 – $6,250

University of Colorado, DenverNCT07815704